首页

Zhaoke Ophthalmology Announces 2022 Interim Results

2022-08-25

3165

First Patient Enrolled in Phase II Clinical Trial of Zhaoke Ophthalmology’s ZKY001 For Transepithelial Photorefractive Keratectomy (TPRK)

2022-08-11

2304

Zhaoke Ophthalmology Completed Patient Enrollments for the Phase III Clinical Trials of the Myopia Progression Treatment Drug NVK002

2022-08-03

2422

First Patient Enrolled for Phase III Clinical Trial of Zhaoke Ophthalmology’s wet Age-related Macular Degeneration (wAMD) Drug, TAB014

2022-07-07

2594

Zhaoke Ophthalmology’s NDA for Cyclosporine A (CsA) Ophthalmic Gel for the Treatment of Dry Eye Disease is Accepted for Review by the CDE

2022-06-09

2685

首页 7 8 9 10 11 尾页

Guangzhou Headquarters

Tel: 020-39062828

E-mail: info@zkoph.com

Add: No. 1 Meide 3rd Road, Pearl River Industrial Park, Nansha District, Guangzhou

Hong Kong Headquarters

Tel: (852)23145100

E-mail: info@zkoph.com

Add: Unit 716, 7/F, Building 12W Phase 3, Hong Kong Science Park Shatin, Hong Kong

Wechat

Guangzhou Headquarters

Tel: 020-39062888

E-mail: info@zkoph.com

Add: No. 1 Meide 3rd Road, Pearl River Industrial Park, Nansha District, Guangzhou

Hong Kong Headquarters

Tel: (852)23145100

E-mail: info@zkoph.com

Add: Unit 716, 7/F, Building 12W Phase 3, Hong Kong Science Park Shatin, Hong Kong

Wechat